Business
Notice of Preliminary Results
Notice of Preliminary Results.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 1566T Angle PLC 02 July 2018 \n\n\n\n\nFor immediate release\n\n\n2 July 2018\n\n\n\n \nANGLE plc (\"the Company\")\n \nNotification of Preliminary Results and Webcast\n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 30 April 2018 on Wednesday 25 July 2018. \n \nA meeting for analysts will be held at 10:30am on 25 July 2018 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London EC1A 4HD. \n \nA live webcast of the analyst meeting may be accessed via ANGLE's Investor Centre page, https://angleplc.com/investor-relations/corporate-presentations/. Please log on to the webcast approximately 5 minutes before 10:30am on the day of the results.\n \nA recording of the webcast will be made available on ANGLE's website following the results meeting.\n \n \nFor further information ANGLE:\n \n\n\n\nANGLE plc\n\n\n+44 (0) 1483 343434\n\n\n\n\nAndrew Newland, Chief Executive\nIan Griffiths, Finance Director\n \n\n\n\n\n\n\n\nfinnCap Ltd (NOMAD and Joint Broker)\nCorporate Finance - Adrian Hargrave, Simon Hicks, Max Bullen-Smith\nCorporate Broking - Alice Lane, Nikita Jain \n \n\n\n+44 (0)20 7220 0500\n\n\n\n\nWG Partners (Joint Broker)\nNigel Barnes, Nigel Birks, Andrew Craig, Chris Lee \n \n\n\n+44 (0) 203 705 9330\n \n \n\n\n\n\nFTI Consulting\nSimon Conway, Mo Noonan, Stephanie Cuthbert\nEvan Smith, Anne Troy (US) \n\n\n \n+44 (0) 203 727 1000\n+1 212 850 5612\n\n\n\n \n \nFor Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/\n \nNotes for editors\n \nAbout ANGLE plc www.angleplc.com \nANGLE is a world leading liquid biopsy company with sample to answer solutions. ANGLE's proven patent protected platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.\n \nANGLE's cell separation technology is called the ParsortixTM system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in E...